Terns Pharmaceuticals, Inc.
TERN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $70 | $63 | $40 | $31 |
| G&A Expenses | $32 | $39 | $22 | $20 |
| SG&A Expenses | $32 | $39 | $22 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $102 | $103 | $62 | $51 |
| Operating Income | -$102 | -$103 | -$62 | -$50 |
| % Margin | – | – | – | -4,986% |
| Other Income/Exp. Net | $13 | $13 | $2 | $0 |
| Pre-Tax Income | -$89 | -$90 | -$60 | -$50 |
| Tax Expense | $0 | $0 | $0 | $1 |
| Net Income | -$89 | -$90 | -$60 | -$50 |
| % Margin | – | – | – | -5,015.8% |
| EPS | -1.12 | -1.27 | -1.67 | -1.98 |
| % Growth | 11.8% | 24% | 15.7% | – |
| EPS Diluted | -1.12 | -1.27 | -1.67 | -1.98 |
| Weighted Avg Shares Out | 80 | 71 | 36 | 25 |
| Weighted Avg Shares Out Dil | 80 | 71 | 36 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $13 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$101 | -$102 | -$61 | -$49 |
| % Margin | – | – | – | -4,934.8% |